<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03295188</url>
  </required_header>
  <id_info>
    <org_study_id>Pls2017-01</org_study_id>
    <nct_id>NCT03295188</nct_id>
  </id_info>
  <brief_title>Effects of Plasmalogen on Obese Subjects</brief_title>
  <official_title>A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Effects of Scallop-derived Plasmalogen on Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japanese Plasmalogen Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Japanese Plasmalogen Society</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12-week, randomized, double-blind, placebo-controlled study to evaluate the effects
      of scallop-derived plasmalogen on brain fatigue, body weight and changes in blood plasmalogen
      in obese subjects aged 20-75 years old.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Profile of Mood States 2nd Edition (POMS 2)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Psychological rating scale to assess transient feelings and mood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist diameter</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood levels of plasmalogen</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Athens Insomnia Scale (AIS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Self-assessment psychometric tool to quantify sleep difficulty</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in adiponectin, leptin, IRI, GA, and high sensitive quantitation of C-reactive protein</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 0.5 mg plasmalogen capsules per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two placebo capsules containing no plasmalogen per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Plasmalogen</intervention_name>
    <description>Treatment group takes two 0.5 mg plasmalogen capsules per day for 12 weeks.</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Group takes two placebo capsules per day for 12 weeks.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willingness to provide informed consent to participate in the study

          -  BMI ≥ 25 ㎏/㎡

          -  HbA1C ≺ 8% without antidiabetic medication in the previous 3 months

          -  Stable medication for 3 months prior to the enrollment, and expectedly throughout the
             course of study

        Exclusion Criteria:

          -  Scallop allergy

          -  Symptomatic obesity, i.e., endocrinal, hypothalamic or drug-induced obesity

          -  Hypertension under medication with 4 or more drugs

          -  Hepatic disorder with AST ≥ 5 times upper limit of the normal range

          -  Mental disorder including schizophrenia and neurosis

          -  Alcohol dependence

          -  History of malignancy for which treatment completed in the past 5 years

          -  Inflammatory disease

          -  Use of plasmalogen supplement in the past 3 months

          -  Ineligible condition as determined by study physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takehiko Fujino</last_name>
    <role>Study Chair</role>
    <affiliation>BOOCS Clinic Fukuoka</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chikako Wakana</last_name>
    <phone>+81 92 283 6852</phone>
    <email>wakana@boocsclinic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>BOOCS Clinic Fukuoka</name>
      <address>
        <city>Fukuoka</city>
        <zip>8120025</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chikako Wakana</last_name>
      <phone>+81 92 283 6852</phone>
      <email>wakana@boocsclinic.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2017</study_first_submitted>
  <study_first_submitted_qc>September 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2017</study_first_posted>
  <last_update_submitted>September 24, 2017</last_update_submitted>
  <last_update_submitted_qc>September 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

